With lawsuits looming, OxyContin maker considers bankruptcy The company that made billions selling OxyContin says it is considering bankruptcy protection as trial dates for opioid lawsuits get closer

The company that has made billions selling the prescription painkiller OxyContin said Wednesday that it is considering legal options including bankruptcy, a move that could upend hundreds of lawsuits claiming it had a major role in causing the U.S. opioid drug crisis.

"As the company has stated, it is exploring and preparing for any number of eventualities and options, given the amount of litigation the company currently faces," Purdue Pharma spokesman Robert Josephson said in an email to The Associated Press. "A decision has not been made to file for bankruptcy, nor is there a timetable."

Such a move has been seen as a strong possibility as the privately held company hired an executive and consultants that specialize in helping companies restructure in the past year.

The company is owned by members of the Sackler family, who have given money to museums around the world, including the Smithsonian Institution in Washington, New York City's Metropolitan Museum of Art and London's Tate Modern. A court filing made public in Massachusetts earlier this year asserts that members of the family were paid more than $4 billion from Purdue from 2007 to 2018.

The first trial date is nearing in hundreds of lawsuits aiming to hold the company and others in the drug industry accountable for the nationwide opioid crisis.

Bankruptcy proceedings would likely pause that litigation, at least for Purdue.

A federal bankruptcy judge would have wide discretion on how to proceed, which could impact the claims of hundreds of local and state governments that have sued. The judge could let claims against other drugmakers and distributors move ahead while Purdue is handled separately, consolidate all of them or let the other claims continue without Purdue involved. Another possibility is that the bankruptcy filing includes a settlement with plaintiffs in the suits.

The lawsuits assert the Stamford, Connecticut-based company aggressively sold OxyContin as a drug with a low chance of triggering addictions despite knowing that wasn't true.

Since OxyContin, a time-released opioid, was introduced in 1996, addiction and overdoses to opioids have surged. In 2017, opioids were involved in nearly 48,000 deaths — a record, according to the U.S. Centers for Disease Control and Prevention.

In recent years, there have been more deaths involving illicit opioids, including heroin and fentanyl, than the prescription forms of the drugs. That change has happened as awareness of the dangers of prescription opioids has increased and prescribers have become more cautious.

Purdue's drugs are just a slice of the opioids prescribed, but critics assign a lot of the blame to the company because of it developed both the drug and an aggressive marketing strategy.

According to a lawsuit filed by the Massachusetts attorney general, the company pushed big sales of OxyContin from the start. Doing so meant persuading doctors who had been reluctant to prescribe such strong painkillers that this one was safe.

In court filings, Purdue has pointed out that its products were approved by federal regulators and prescribed by doctors.

A federal judge overseeing more than 1,300 of the cases against Purdue and other companies has been pushing the parties to reach a grand settlement that would make a difference in the opioid crisis. The judge, Cleveland-based Dan Polster, has scheduled a trial for the claims brought by Ohio's Cuyahoga and Summit Counties for October.

An Oklahoma state court has scheduled a trial in a case brought by that state for May. If it goes to trial, it would be the first of the wave of recent claims against opioid companies to do so.

Purdue's statement to the AP came the same day The Washington Post published a story in which company president and CEO Craig Landau acknowledged bankruptcy is under consideration.

One lawyer who is suing Purdue on behalf of clients including the city of Albuquerque and the state of Utah said it's long been thought that Purdue couldn't afford to pay the massive amounts being sought in the lawsuits.

"I don't think there's enough money in that company to pay for the damages that are claimed," said Jonathan Novak.

Abbe Gluck, a Yale Law School professor who has followed the case, said even if the Oklahoma trial moved ahead "nobody is going to get paid ... without coming to the bankruptcy court, once Purdue files."

There's a history of bankruptcy claims by organizations facing big lawsuits. Dozens of asbestos companies have done so since the 1980s. Last year, USA Gymnastics filed for protection as it faced lawsuits over sexual abuse by team doctor Larry Nassar. Earlier this year, Pacific Gas & Electric Corp. sought bankruptcy protection because it faces billions of dollars in potential damages from lawsuits over catastrophic wildfires in California.

Vincent Buccola, a lawyer and professor of business ethics, said Purdue may be trying to avoid going to court in states that have been heavily impacted by the opioid epidemic.

"That's not the jury you want to face," said Buccola, who teaches at University of Pennsylvania. "So you might try to stop that litigation from happening and consolidate it in front of bankruptcy judge who you hope will be more favorable."

A bankruptcy judge could pressure plaintiffs to settle with the company if they want to get any damages at all, Buccola said.

———

Follow Mulvihill at http://www.twitter.com/geoffmulvihill and Perrone at http://www.twitter.com/AP—FDAwriter